A Phase Ib, Open-Label, Dose-Escalation Study Of The Safety, Tolerability, and Pharmacokinetics of Cobimetinib and GDC-0994 In Patients With Locally Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 10 Apr 2017
At a glance
- Drugs Ravoxertinib (Primary) ; Cobimetinib
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Genentech
- 05 Apr 2017 Results assessing safety and tolerability, pharmacokinetics and preliminary efficacy, presented at the 108th Annual Meeting of the American Association for Cancer Research
- 05 Apr 2017 Status changed from active, no longer recruiting to completed.
- 01 Jun 2016 Status changed from recruiting to active, no longer recruiting.